2024年第四季度Apyx Medical GAAP每股收益$(0.12)优于预期$(0.15),销售额$1422万超过预期$1339万

财报速递
13 Mar
Apyx Medical(NASDAQ:APYX)公布的季度亏损为每股$(0.12),优于分析师一致预期的$(0.15),超出预期20%。相比去年同期每股$(0.28)的亏损,实现了57.14%的增长。公司报告的季度销售额为$1422万,超过分析师一致预期的$1339万,超出预期6.21%。相比去年同期的$1466万,销售额下降了3.01%。

以上内容来自Benzinga Earnings专栏,原文如下:

Apyx Medical (NASDAQ:APYX) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.15) by 20 percent. This is a 57.14 percent increase over losses of $(0.28) per share from the same period last year. The company reported quarterly sales of $14.22 million which beat the analyst consensus estimate of $13.39 million by 6.21 percent. This is a 3.01 percent decrease over sales of $14.66 million the same period last year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10